Figure 11
From: An immune gene signature to predict prognosis and immunotherapeutic response in lung adenocarcinoma
The prognostic value of IGSPP for ICI treatment. (A–D) Scores of TIDE, MSI, T cell exclusion and T cell dysfunction in different IGSPP groups. The Wilcoxon test was used to evaluate the difference (*P < 0.05, **P < 0.01, ***P < 0.001). (E–G) The 1-, 3- and 5-year ROC curves based on the IGSPP, TIS and TIDE scores of the TCGA cohort.
